In the remaining 7 TKI-naive patients, the ORR was 57% (95% CI 25–84%) and responses were observed in ALK-rearranged NSCLC, renal cell carcinoma, and colorectal cancer. The gene discussed is ALK; the disease is non-small cell lung carcinoma.